Abstract
The spread of the omicron variant produced an increase in Covid-19 in Israel in late 2021, and a second boost of BNT162b2 vaccine was authorized in early January 2022. This article reports the efficacy of the fourth dose among Israeli citizens 60 years of age or older. Rates of severe illness were reduced by a factor of 3.5 in the fourth week after the second boost.
Original language | English |
---|---|
Pages (from-to) | 1712-1720 |
Number of pages | 9 |
Journal | New England Journal of Medicine |
Volume | 386 |
Issue number | 18 |
Early online date | 5 May 2022 |
DOIs | |
State | Published - 5 May 2022 |
All Science Journal Classification (ASJC) codes
- General Medicine